-
Myelodysplastic syndromes (MDS) usually occur in older adults and, as such, comorbid conditions are common. The investigators found that among 418 MDS patients, at least one comorbid condition existed in 93% at diagnosis. Comorbidity scores were generated using three common scoring systems: the HCT-CI, MDS-CI, and CCI. Worse survival was linked to higher CCI (p = 0.01) and MDS-CI (p = 0.02) but not HCT-CI. Higher CCI scores were associated with non-leukemic death and progression of red blood cell dependency, whereas higher comorbidity by HCT-CI and MDS-CI did not. Higher comorbid burden by CCI in MDS predicts for worse survival and non-leukemic death. Comorbidity data may help refine prognosis for MDS patients.
-
Escitalopram for menopausal hot flashes, rifaximin for IBS without constipation, herpes zoster vaccination, antiepileptics drugs and fracture risk, and FDA Actions.
-
A 58-year-old retired school principal was seen in the office because of malaise and weight loss. He had been well until 4 years ago when he was discovered, at a routine annual exam, to have lymphocytosis.
-
Statins and liver function; dosing timing for thyroxine; rivaroxaban for VTE, DVT, and stroke; echinacea and the common cold; and FDA actions.
-
With the development of an increased understanding of cellular biology, in general, and the regulation of eosinophils, in particular, the heterogeneous diagnosis of hypereosinophilic Syndrome (HES) has now been better defined and a classification system has been developed with clear clinical implications.
-
Very limited data are available on autologous transplant outcomes for uncommon or rare multiple myeloma (MM) subtypes.
-
The occurrence of skin rash in patients receiving cetuximab is common, and for patients with colon cancer, this has been associated with better clinical outcomes.
-
-
A 74-year retired veterinarian presents to the emergency department (ED) with shortness of breath. He was recently diagnosed with diffuse large-cell lymphoma with prominent abdominal lymphadenopathy and positive bone marrow and has been treated with two cycles of R-CHOP.
-
The U.S. Food and Drug Administration (FDA) has recently approved denosumab for the prevention of skeletal-related events in patients with bone metastases from solid tumors.
